Preliminary HER2 expression data from NeuACT, the phase II randomized, open-label trial of DN24-02 in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.

Authors

Michael F. Press

University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

Michael F. Press , Peter H. O'Donnell , Elizabeth R. Plimack , Jean H. Hoffman-Censits , David I. Quinn , Padmanee Sharma , Todd DeVries , Melissa Chen , Michael Locker , Dean F. Bajorin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 Genitourinary Cancers Symposium

bookmark_border

HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2.

First Author: Michael F. Press

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence.

First Author: Dean F. Bajorin

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.

First Author: Dean F. Bajorin

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence.

First Author: D. F. Bajorin